Literature DB >> 16478695

Elimination mechanisms of therapeutic monoclonal antibodies.

Mohammad A Tabrizi1, Chih-Ming L Tseng, Lorin K Roskos.   

Abstract

Targeted therapies using monoclonal antibodies have achieved important therapeutic applications in the treatment of various human diseases. Understanding the factors that impact the pharmacokinetics of monoclonal antibodies is of high importance for effective therapy. Many factors related to the target antigen, antibody and patients can affect antibody elimination. Evaluation of these factors will facilitate the understanding of the processes involved in antibody elimination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478695     DOI: 10.1016/S1359-6446(05)03638-X

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  146 in total

Review 1.  Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab.

Authors:  Bing-Bing Yang; Peggy Lum; Alin Chen; Rosalin Arends; Lorin Roskos; Brian Smith; Juan José Pérez Ruixo
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

Review 3.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 4.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

5.  An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Authors:  Chad K Oh; Raffaella Faggioni; Feng Jin; Lorin K Roskos; Bing Wang; Claire Birrell; Rosamund Wilson; Nestor A Molfino
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

7.  Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability.

Authors:  Maria A Miller; Tarik A Khan; Kevin J Kaczorowski; Brian K Wilson; Aileen K Dinin; Ameya U Borwankar; Miguel A Rodrigues; Thomas M Truskett; Keith P Johnston; Jennifer A Maynard
Journal:  J Pharm Sci       Date:  2012-07-06       Impact factor: 3.534

8.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Authors:  Yanguang Cao; Joseph P Balthasar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-31       Impact factor: 2.745

Review 9.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

Review 10.  Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Authors:  Y Zhang; S Doshi; M Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-05-26       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.